Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IGMS IGM Biosciences > Company Profile
IGMS IGM Biosciences
21.000
-1.010-4.59%
Post Mkt Price
21.0000.0000.00%
Symbol
IGMS
Company Name
IGM Biosciences
Listing Date
09/18/2019
Establishment Date
2010
CEO
Mr. Fred Schwarzer
Market
NASDAQ
Employees
192
Securities Type
DR
Fiscal Year Ends
12-31
Address
325 East Middlefield Road
City
Mountain View
Province
California
Country
United States of America
Zip code
94043
Phone
1-650-965-7873
Profile
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Company Overview
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
CEO: Mr. Fred Schwarzer
Market: NASDAQ
Listing Date: 09/18/2019
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist